Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center, founded in 1898 by Dr. Roswell Park. RPCI is the only upstate New York facility to hold the National Cancer Center designation of Comprehensive Cancer Center and to serve as a member of the prestigious National Comprehensive Cancer Network. The campus spans 25 acres in downtown Buffalo and consists of 15 buildings with about one million square feet of space.
Access to frontline therapies Roswell Park Cancer Institute has been at the forefront in developing and delivering innovative cancer therapies since 1904, when the Institute launched the first chemotherapy trials in the world. As a result of its aggressive clinical research studies program, RPCI is able to offer many frontline therapies long before they are available at most other institutions. Of special note:
- Roswell Park is one of only a handful of centers in the U.S. that offers high-dose interleukin-2 (IL-2) therapy, which has the greatest potential for triggering a significant response in cases of metastatic kidney cancer and malignant melanoma. RPCI has provided this option for nearly a decade, during which time the staff have developed special expertise in the care of patients who receive this therapy.
- Roswell Park is a leader in delivering the latest and most promising therapies, and was among the first institutions to offer Erbitux for the treatment of colon cancer, before its approval by the U.S. Food and Drug Administration.
- Roswell Park maintains a dedicated oncology pharmacy that custom-mixes each dose for the individual patient; we do not use pre-mixed or pre-packaged unit doses. Our staff includes PharmDs, who are pharmacists with concentrated training in oncology.
- Roswell Park’s cancer programs are disease-specific, with teams that work within a single location called a Center. Teams include medical, surgical and radiation oncologists; pathologists; nurses; and nurse practitioners, who work together to develop an individualized care plan for each patient, from diagnosis through recovery.
- Roswell Park played a leading role in clinical studies that led to U.S. Food and Drug Administration approval of the use of lenalidomide (Revlimid®), in combination with dexamethasone, for the treatment of multiple myeloma. RPCI is also conducting pioneering clinical trials on lenalidomide to evaluate its effectiveness in treating chronic lymphocytic leukemia (CLL). In addition, the Myeloma and CLL Program at RPCI is investigating several novel drugs for the treatment of these disorders.
- Roswell Park has been a major contributor to clinical studies on Rituxan, the first monoclonal antibody to be approved by the U.S. Food and Drug Administration for the treatment of non-Hodgkin’s lymphoma.
- Roswell Park led a national, multi-center trial evaluating the use of Gleevec and Genasense in combination for the treatment of chronic myeloid leukemia (CML). Roswell Park also leads a national multi-center trial evaluating the use of Gleevec upfront for newly diagnosed acute lymphoblastic leukemia (CALGB 10001).
In the fall of 2007, Roswell Park will open a new Clinical Research Center designed specifically for the care of patients participating in clinical research studies and the collection of data from those studies. It will enable Roswell Park to launch more studies focusing on novel agents, especially for cancers for which there are very few treatment options, and to qualify to participate in many more studies of the latest drugs being sponsored by the National Cancer Institute (NCI) and pharmaceutical companies.